Conference Recap

The 2022 CHEST Annual Meeting had several important studies on lung cancer.

Douglas Arenberg, MD, FCCP from the University of Michigan Northville Health Center, reports on content from two papers that focus on the first million persons to have been screened for lung cancer after the initial launch of the American College of Radiology Lung Cancer Screening Registry. The research showed that the medical community is, in fact, doing well in some areas of lung cancer screening but that improvements need to be made in order to reach former tobacco users, who would greatly benefit from these screenings. 

He also highlights a series of studies that were discussed regarding smoking cessation at lung evaluations known as the SCALE Collaboration. Effective smoking interventions could enhance the benefits of lung cancer screening by reducing mortality and morbidity resulting from lung cancer.

Finally, Dr Arenberg shares a series of presentations that highlight how the surgical treatment of early-stage lung cancer is creating significant changes in the standard of care.

--

Douglas Arenberg, MD, FCCP Professor of Medicine, Department of Internal Medicine, Division of Pulmonary & Critical Care, University of Michigan; Director of Bronchoscopy and Medical Director for the Lung Cancer Screening and Lung Nodule Clinics, University of Michigan, Ann Arbor, Michigan 

Douglas Arenberg, MD, FCCP has disclosed no relevant financial relationships. 

The 2022 CHEST Annual Meeting had several important studies on lung cancer.

Douglas Arenberg, MD, FCCP from the University of Michigan Northville Health Center, reports on content from two papers that focus on the first million persons to have been screened for lung cancer after the initial launch of the American College of Radiology Lung Cancer Screening Registry. The research showed that the medical community is, in fact, doing well in some areas of lung cancer screening but that improvements need to be made in order to reach former tobacco users, who would greatly benefit from these screenings. 

He also highlights a series of studies that were discussed regarding smoking cessation at lung evaluations known as the SCALE Collaboration. Effective smoking interventions could enhance the benefits of lung cancer screening by reducing mortality and morbidity resulting from lung cancer.

Finally, Dr Arenberg shares a series of presentations that highlight how the surgical treatment of early-stage lung cancer is creating significant changes in the standard of care.

--

Douglas Arenberg, MD, FCCP Professor of Medicine, Department of Internal Medicine, Division of Pulmonary & Critical Care, University of Michigan; Director of Bronchoscopy and Medical Director for the Lung Cancer Screening and Lung Nodule Clinics, University of Michigan, Ann Arbor, Michigan 

Douglas Arenberg, MD, FCCP has disclosed no relevant financial relationships. 

The 2022 CHEST Annual Meeting had several important studies on lung cancer.

Douglas Arenberg, MD, FCCP from the University of Michigan Northville Health Center, reports on content from two papers that focus on the first million persons to have been screened for lung cancer after the initial launch of the American College of Radiology Lung Cancer Screening Registry. The research showed that the medical community is, in fact, doing well in some areas of lung cancer screening but that improvements need to be made in order to reach former tobacco users, who would greatly benefit from these screenings. 

He also highlights a series of studies that were discussed regarding smoking cessation at lung evaluations known as the SCALE Collaboration. Effective smoking interventions could enhance the benefits of lung cancer screening by reducing mortality and morbidity resulting from lung cancer.

Finally, Dr Arenberg shares a series of presentations that highlight how the surgical treatment of early-stage lung cancer is creating significant changes in the standard of care.

--

Douglas Arenberg, MD, FCCP Professor of Medicine, Department of Internal Medicine, Division of Pulmonary & Critical Care, University of Michigan; Director of Bronchoscopy and Medical Director for the Lung Cancer Screening and Lung Nodule Clinics, University of Michigan, Ann Arbor, Michigan 

Douglas Arenberg, MD, FCCP has disclosed no relevant financial relationships. 

Key data on chronic conditions in type 2 diabetes, presented at the 2022 European Association for the Study of Diabetes (EASD), are discussed by Dr Carol Wysham, from the University of Washington School of Medicine. 

Focusing on nonalcoholic fatty liver disease (NAFLD), Dr Wysham reports on a large national registry out of Sweden that explored the rates of microvascular complications in patients with NAFLD. The study showed that NAFLD is independently associated with chronic kidney disease and retinopathy. Coupling the findings with the rise in diabetes risk per population, the presence of NAFLD may represent an additional risk factor for microvascular complications.  

Next, Dr Wysham comments on another large, real-world study using data from the UK National Health Service (NHS), investigating a scoring system for noninvasive fibrosis, which the study concludes is a promising prognostic biomarker of liver and cardiovascular events in adults with type 2 diabetes.  

She then turns to a clinical study that evaluated whether the 2018 EASD/ADA routine treatment recommendation algorithm is associated with decreasing cardiovascular events and death in type 2 diabetes. The study found that nonadherence to the recommendations was associated with an increase in major adverse cardiovascular events and mortality.

--

Carol Wysham, MD, Clinical Professor of Medicine, Department of Medicine, University of Washington School of Medicine; Clinical Endocrinologist, Rockwood Center for Diabetes and Endocrinology, MultiCare Health Systems, Spokane, Washington 

Carol Wysham, MD, has disclosed the following relevant financial relationships: 

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Endocrine Society; MultiCare Health Systems 

Received research grant from: Allergan; Abbott; Corcept; Eli Lilly; Mylan; Novo Nordisk; Regeneron 

Key data on chronic conditions in type 2 diabetes, presented at the 2022 European Association for the Study of Diabetes (EASD), are discussed by Dr Carol Wysham, from the University of Washington School of Medicine. 

Focusing on nonalcoholic fatty liver disease (NAFLD), Dr Wysham reports on a large national registry out of Sweden that explored the rates of microvascular complications in patients with NAFLD. The study showed that NAFLD is independently associated with chronic kidney disease and retinopathy. Coupling the findings with the rise in diabetes risk per population, the presence of NAFLD may represent an additional risk factor for microvascular complications.  

Next, Dr Wysham comments on another large, real-world study using data from the UK National Health Service (NHS), investigating a scoring system for noninvasive fibrosis, which the study concludes is a promising prognostic biomarker of liver and cardiovascular events in adults with type 2 diabetes.  

She then turns to a clinical study that evaluated whether the 2018 EASD/ADA routine treatment recommendation algorithm is associated with decreasing cardiovascular events and death in type 2 diabetes. The study found that nonadherence to the recommendations was associated with an increase in major adverse cardiovascular events and mortality.

--

Carol Wysham, MD, Clinical Professor of Medicine, Department of Medicine, University of Washington School of Medicine; Clinical Endocrinologist, Rockwood Center for Diabetes and Endocrinology, MultiCare Health Systems, Spokane, Washington 

Carol Wysham, MD, has disclosed the following relevant financial relationships: 

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Endocrine Society; MultiCare Health Systems 

Received research grant from: Allergan; Abbott; Corcept; Eli Lilly; Mylan; Novo Nordisk; Regeneron 

Key data on chronic conditions in type 2 diabetes, presented at the 2022 European Association for the Study of Diabetes (EASD), are discussed by Dr Carol Wysham, from the University of Washington School of Medicine. 

Focusing on nonalcoholic fatty liver disease (NAFLD), Dr Wysham reports on a large national registry out of Sweden that explored the rates of microvascular complications in patients with NAFLD. The study showed that NAFLD is independently associated with chronic kidney disease and retinopathy. Coupling the findings with the rise in diabetes risk per population, the presence of NAFLD may represent an additional risk factor for microvascular complications.  

Next, Dr Wysham comments on another large, real-world study using data from the UK National Health Service (NHS), investigating a scoring system for noninvasive fibrosis, which the study concludes is a promising prognostic biomarker of liver and cardiovascular events in adults with type 2 diabetes.  

She then turns to a clinical study that evaluated whether the 2018 EASD/ADA routine treatment recommendation algorithm is associated with decreasing cardiovascular events and death in type 2 diabetes. The study found that nonadherence to the recommendations was associated with an increase in major adverse cardiovascular events and mortality.

--

Carol Wysham, MD, Clinical Professor of Medicine, Department of Medicine, University of Washington School of Medicine; Clinical Endocrinologist, Rockwood Center for Diabetes and Endocrinology, MultiCare Health Systems, Spokane, Washington 

Carol Wysham, MD, has disclosed the following relevant financial relationships: 

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Endocrine Society; MultiCare Health Systems 

Received research grant from: Allergan; Abbott; Corcept; Eli Lilly; Mylan; Novo Nordisk; Regeneron 

Dr Anne Peters, of the Keck School of Medicine of the University of Southern California, reports on the latest guidelines and updates in glycemic control for persons with type 2 diabetes, as presented at the 2022 European Association for the Study of Diabetes (EASD).  

Dr Peters opens by reporting on the eagerly awaited joint ADA/EASD guidelines on the management of hyperglycemia in type 2 diabetes. The updated guidelines emphasize weight goals and holistic person-centered care as essential components of comprehensive management.  

Next, Dr Peters comments on the report of the 44-year UK Prospective Diabetes Study (UKPDS), which demonstrated the benefits of early intensive blood glucose control over decades. The study began tracking volunteers in 1977 and continued until 2021.  

Finally, Dr Peters reports on a real-world data study examining gender disparities in the time to initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease. The study showed that although the therapeutic initiation rate for woman and men is comparable after stroke and peripheral arterial disease, men are prescribed cardioprotective glucose-lowering drugs faster than women when diagnosed with heart failure or ischemic heart disease.  

--

Anne L. Peters, MD, Professor, Department of Clinical Medicine, Clinical Scholar, Keck School of Medicine of the University of Southern California; Director, USC Clinical Diabetes Programs, University of Southern California Westside Center for Diabetes, Los Angeles, California 

Anne L. Peters, MD, has disclosed the following relevant financial relationships:  

Serve(d) as a director, officer, partner, employee, advisor, consultant, or a trustee for: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi 

Received research grant from: Insulet; Dexcom; Abbott  

Received income in an amount equal to or greater than $250 from: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi; Insulet; Dexcom 

Stock options from: Teladoc; Omada Health (not even close to 5% equity) 

Dr Anne Peters, of the Keck School of Medicine of the University of Southern California, reports on the latest guidelines and updates in glycemic control for persons with type 2 diabetes, as presented at the 2022 European Association for the Study of Diabetes (EASD).  

Dr Peters opens by reporting on the eagerly awaited joint ADA/EASD guidelines on the management of hyperglycemia in type 2 diabetes. The updated guidelines emphasize weight goals and holistic person-centered care as essential components of comprehensive management.  

Next, Dr Peters comments on the report of the 44-year UK Prospective Diabetes Study (UKPDS), which demonstrated the benefits of early intensive blood glucose control over decades. The study began tracking volunteers in 1977 and continued until 2021.  

Finally, Dr Peters reports on a real-world data study examining gender disparities in the time to initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease. The study showed that although the therapeutic initiation rate for woman and men is comparable after stroke and peripheral arterial disease, men are prescribed cardioprotective glucose-lowering drugs faster than women when diagnosed with heart failure or ischemic heart disease.  

--

Anne L. Peters, MD, Professor, Department of Clinical Medicine, Clinical Scholar, Keck School of Medicine of the University of Southern California; Director, USC Clinical Diabetes Programs, University of Southern California Westside Center for Diabetes, Los Angeles, California 

Anne L. Peters, MD, has disclosed the following relevant financial relationships:  

Serve(d) as a director, officer, partner, employee, advisor, consultant, or a trustee for: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi 

Received research grant from: Insulet; Dexcom; Abbott  

Received income in an amount equal to or greater than $250 from: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi; Insulet; Dexcom 

Stock options from: Teladoc; Omada Health (not even close to 5% equity) 

Dr Anne Peters, of the Keck School of Medicine of the University of Southern California, reports on the latest guidelines and updates in glycemic control for persons with type 2 diabetes, as presented at the 2022 European Association for the Study of Diabetes (EASD).  

Dr Peters opens by reporting on the eagerly awaited joint ADA/EASD guidelines on the management of hyperglycemia in type 2 diabetes. The updated guidelines emphasize weight goals and holistic person-centered care as essential components of comprehensive management.  

Next, Dr Peters comments on the report of the 44-year UK Prospective Diabetes Study (UKPDS), which demonstrated the benefits of early intensive blood glucose control over decades. The study began tracking volunteers in 1977 and continued until 2021.  

Finally, Dr Peters reports on a real-world data study examining gender disparities in the time to initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease. The study showed that although the therapeutic initiation rate for woman and men is comparable after stroke and peripheral arterial disease, men are prescribed cardioprotective glucose-lowering drugs faster than women when diagnosed with heart failure or ischemic heart disease.  

--

Anne L. Peters, MD, Professor, Department of Clinical Medicine, Clinical Scholar, Keck School of Medicine of the University of Southern California; Director, USC Clinical Diabetes Programs, University of Southern California Westside Center for Diabetes, Los Angeles, California 

Anne L. Peters, MD, has disclosed the following relevant financial relationships:  

Serve(d) as a director, officer, partner, employee, advisor, consultant, or a trustee for: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi 

Received research grant from: Insulet; Dexcom; Abbott  

Received income in an amount equal to or greater than $250 from: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi; Insulet; Dexcom 

Stock options from: Teladoc; Omada Health (not even close to 5% equity) 

Dr Anne Peters, of the Keck School of Medicine of the University of Southern California, reports on the latest research on insulin therapy in adults with type 2 diabetes, presented at the European Association for the Study of Diabetes (EASD). 

Dr Peters highlights a clinical study evaluating whether bedtime is optimal for the administration of neutral protamine Hagedorn (NPH) insulin, also known as isophane insulin. The results indicate that titration of NPH plays an important role in avoiding nocturnal hypoglycemia.

Next, Dr Peters discusses the ONWARDS 2 study, a phase 3a trial looking at once-weekly insulin icodec vs once-daily insulin degludec in basal insulin–treated type 2 diabetes. The trial found insulin icodec to be superior to insulin degludec in reducing A1c.

Dr Peters also examines the SoliMix trial, which compared iGlarLixi once daily to twice-daily premix BIAsp 30 in suboptimally controlled type 2 diabetes. The trial evaluated whether patients currently on a basal-bolus regimen would have an equal or more effective response to once-a-day combination therapy. Results showed that iGlarLixi provided better glycemic control and weight benefit than the twice-daily BlAsp 30.

Finally, Dr Peters evaluates a study that looked at switching from a basal-bolus insulin treatment to insulin degludec + liraglutide combination. The combination proved at least as effective as the basal-bolus approach. 

--

Anne L. Peters, MD, Professor, Department of Clinical Medicine, Clinical Scholar, Keck School of Medicine of the University of Southern California; Director, USC Clinical Diabetes Programs, University of Southern California Westside Center for Diabetes, Los Angeles, California

Anne L. Peters, MD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or a trustee for: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi

Received research grant from: Insulet; Dexcom; Abbott

Received income in an amount equal to or greater than $250 from: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi; Insulet; Dexcom

Stock options from: Teladoc; Omada Health (not even close to 5% equity)

Dr Anne Peters, of the Keck School of Medicine of the University of Southern California, reports on the latest research on insulin therapy in adults with type 2 diabetes, presented at the European Association for the Study of Diabetes (EASD). 

Dr Peters highlights a clinical study evaluating whether bedtime is optimal for the administration of neutral protamine Hagedorn (NPH) insulin, also known as isophane insulin. The results indicate that titration of NPH plays an important role in avoiding nocturnal hypoglycemia.

Next, Dr Peters discusses the ONWARDS 2 study, a phase 3a trial looking at once-weekly insulin icodec vs once-daily insulin degludec in basal insulin–treated type 2 diabetes. The trial found insulin icodec to be superior to insulin degludec in reducing A1c.

Dr Peters also examines the SoliMix trial, which compared iGlarLixi once daily to twice-daily premix BIAsp 30 in suboptimally controlled type 2 diabetes. The trial evaluated whether patients currently on a basal-bolus regimen would have an equal or more effective response to once-a-day combination therapy. Results showed that iGlarLixi provided better glycemic control and weight benefit than the twice-daily BlAsp 30.

Finally, Dr Peters evaluates a study that looked at switching from a basal-bolus insulin treatment to insulin degludec + liraglutide combination. The combination proved at least as effective as the basal-bolus approach. 

--

Anne L. Peters, MD, Professor, Department of Clinical Medicine, Clinical Scholar, Keck School of Medicine of the University of Southern California; Director, USC Clinical Diabetes Programs, University of Southern California Westside Center for Diabetes, Los Angeles, California

Anne L. Peters, MD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or a trustee for: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi

Received research grant from: Insulet; Dexcom; Abbott

Received income in an amount equal to or greater than $250 from: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi; Insulet; Dexcom

Stock options from: Teladoc; Omada Health (not even close to 5% equity)

Dr Anne Peters, of the Keck School of Medicine of the University of Southern California, reports on the latest research on insulin therapy in adults with type 2 diabetes, presented at the European Association for the Study of Diabetes (EASD). 

Dr Peters highlights a clinical study evaluating whether bedtime is optimal for the administration of neutral protamine Hagedorn (NPH) insulin, also known as isophane insulin. The results indicate that titration of NPH plays an important role in avoiding nocturnal hypoglycemia.

Next, Dr Peters discusses the ONWARDS 2 study, a phase 3a trial looking at once-weekly insulin icodec vs once-daily insulin degludec in basal insulin–treated type 2 diabetes. The trial found insulin icodec to be superior to insulin degludec in reducing A1c.

Dr Peters also examines the SoliMix trial, which compared iGlarLixi once daily to twice-daily premix BIAsp 30 in suboptimally controlled type 2 diabetes. The trial evaluated whether patients currently on a basal-bolus regimen would have an equal or more effective response to once-a-day combination therapy. Results showed that iGlarLixi provided better glycemic control and weight benefit than the twice-daily BlAsp 30.

Finally, Dr Peters evaluates a study that looked at switching from a basal-bolus insulin treatment to insulin degludec + liraglutide combination. The combination proved at least as effective as the basal-bolus approach. 

--

Anne L. Peters, MD, Professor, Department of Clinical Medicine, Clinical Scholar, Keck School of Medicine of the University of Southern California; Director, USC Clinical Diabetes Programs, University of Southern California Westside Center for Diabetes, Los Angeles, California

Anne L. Peters, MD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or a trustee for: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi

Received research grant from: Insulet; Dexcom; Abbott

Received income in an amount equal to or greater than $250 from: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi; Insulet; Dexcom

Stock options from: Teladoc; Omada Health (not even close to 5% equity)

Highlights in advanced non–small lung cancer (NSCLC) from the 2022 European Society for Medical Oncology Congress are presented by Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California.

Dr West begins by discussing CodeBreak 200, a study comparing sotorasib with docetaxel in previously treated patients with a KRAS G12C mutation. Sotorasib improved progression-free survival, but overall survival data are awaited.

Next, Dr West examines 5-year updates from KEYNOTE-189 and KEYNOTE-407, comparing pembrolizumab with chemotherapy in nonsquamous and squamous disease, respectively. Around two fifths of patients remained alive and disease-free 5 years after stopping treatment.

Dr West then reports on the IPSOS trial, which compared atezolizumab with single-agent chemotherapy in patients who were ineligible for standard chemotherapy. The results suggested that immunotherapy could be used in patients who are usually excluded from trials.

He finishes with two studies in EGFR-mutated disease. ORIENT-3 indicated that the effect of sintilimab could be boosted with a bevacizumab biosimilar. INSIGHT 2 suggested that adding tepotinib to osimertinib may be effective in patients with MET amplification.

--

Associate Professor, Department of Medical Oncology, City of Hope Comprehensive Cancer Care, Duarte, California; Medical Director, AccessHope, Los Angeles, California

Howard (Jack) West, MD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; Eli Lilly; EQRx; Genentech/Roche; Merck; Mirati; Pfizer; Regeneron; Takeda

Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Merck

Highlights in advanced non–small lung cancer (NSCLC) from the 2022 European Society for Medical Oncology Congress are presented by Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California.

Dr West begins by discussing CodeBreak 200, a study comparing sotorasib with docetaxel in previously treated patients with a KRAS G12C mutation. Sotorasib improved progression-free survival, but overall survival data are awaited.

Next, Dr West examines 5-year updates from KEYNOTE-189 and KEYNOTE-407, comparing pembrolizumab with chemotherapy in nonsquamous and squamous disease, respectively. Around two fifths of patients remained alive and disease-free 5 years after stopping treatment.

Dr West then reports on the IPSOS trial, which compared atezolizumab with single-agent chemotherapy in patients who were ineligible for standard chemotherapy. The results suggested that immunotherapy could be used in patients who are usually excluded from trials.

He finishes with two studies in EGFR-mutated disease. ORIENT-3 indicated that the effect of sintilimab could be boosted with a bevacizumab biosimilar. INSIGHT 2 suggested that adding tepotinib to osimertinib may be effective in patients with MET amplification.

--

Associate Professor, Department of Medical Oncology, City of Hope Comprehensive Cancer Care, Duarte, California; Medical Director, AccessHope, Los Angeles, California

Howard (Jack) West, MD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; Eli Lilly; EQRx; Genentech/Roche; Merck; Mirati; Pfizer; Regeneron; Takeda

Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Merck

Highlights in advanced non–small lung cancer (NSCLC) from the 2022 European Society for Medical Oncology Congress are presented by Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California.

Dr West begins by discussing CodeBreak 200, a study comparing sotorasib with docetaxel in previously treated patients with a KRAS G12C mutation. Sotorasib improved progression-free survival, but overall survival data are awaited.

Next, Dr West examines 5-year updates from KEYNOTE-189 and KEYNOTE-407, comparing pembrolizumab with chemotherapy in nonsquamous and squamous disease, respectively. Around two fifths of patients remained alive and disease-free 5 years after stopping treatment.

Dr West then reports on the IPSOS trial, which compared atezolizumab with single-agent chemotherapy in patients who were ineligible for standard chemotherapy. The results suggested that immunotherapy could be used in patients who are usually excluded from trials.

He finishes with two studies in EGFR-mutated disease. ORIENT-3 indicated that the effect of sintilimab could be boosted with a bevacizumab biosimilar. INSIGHT 2 suggested that adding tepotinib to osimertinib may be effective in patients with MET amplification.

--

Associate Professor, Department of Medical Oncology, City of Hope Comprehensive Cancer Care, Duarte, California; Medical Director, AccessHope, Los Angeles, California

Howard (Jack) West, MD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; Eli Lilly; EQRx; Genentech/Roche; Merck; Mirati; Pfizer; Regeneron; Takeda

Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Merck

Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California, discusses key presentations on early-stage non–small lung cancer (NSCLC) from the 2022 European Society for Medical Oncology Congress.

He begins by reporting on 2 years of additional follow-up from the ADAURA trial, which looked at osimertinib as adjuvant therapy in patients with resected EGFR-mutated disease. The results raise the question of whether the drug needs to be given indefinitely.

Next, he discusses an analysis of data from the ADAURA trial that looked at longitudinal monitoring of circulating tumor DNA (ctDNA) levels. This revealed that both baseline ctDNA and ctDNA clearance were predictive of later recurrence.

Dr West moves on to a large global study that demonstrated a clear link between air pollution and lung cancer. Pollution was shown to be a tumor promoter of rare driver mutations in normal lung tissue.

After discussing disappointing data from CANOPY-A indicating that adjuvant canakinumab does not improve survival outcomes, he closes with an examination of the PATHFINDER study. This involved more than 6600 patients who were screened for cancer after a single blood test. Although the study identified cancer in 1.4% of participants, the low positive predictive value raises questions over the wider application of this test.

--

Associate Professor, Department of Medical Oncology, City of Hope Comprehensive Cancer Care, Duarte, California; Medical Director, AccessHope, Los Angeles, California

Howard (Jack) West, MD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; Eli Lilly; EQRx; Genentech/Roche; Merck; Mirati; Pfizer; Regeneron; Takeda

Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Merck

Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California, discusses key presentations on early-stage non–small lung cancer (NSCLC) from the 2022 European Society for Medical Oncology Congress.

He begins by reporting on 2 years of additional follow-up from the ADAURA trial, which looked at osimertinib as adjuvant therapy in patients with resected EGFR-mutated disease. The results raise the question of whether the drug needs to be given indefinitely.

Next, he discusses an analysis of data from the ADAURA trial that looked at longitudinal monitoring of circulating tumor DNA (ctDNA) levels. This revealed that both baseline ctDNA and ctDNA clearance were predictive of later recurrence.

Dr West moves on to a large global study that demonstrated a clear link between air pollution and lung cancer. Pollution was shown to be a tumor promoter of rare driver mutations in normal lung tissue.

After discussing disappointing data from CANOPY-A indicating that adjuvant canakinumab does not improve survival outcomes, he closes with an examination of the PATHFINDER study. This involved more than 6600 patients who were screened for cancer after a single blood test. Although the study identified cancer in 1.4% of participants, the low positive predictive value raises questions over the wider application of this test.

--

Associate Professor, Department of Medical Oncology, City of Hope Comprehensive Cancer Care, Duarte, California; Medical Director, AccessHope, Los Angeles, California

Howard (Jack) West, MD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; Eli Lilly; EQRx; Genentech/Roche; Merck; Mirati; Pfizer; Regeneron; Takeda

Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Merck

Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California, discusses key presentations on early-stage non–small lung cancer (NSCLC) from the 2022 European Society for Medical Oncology Congress.

He begins by reporting on 2 years of additional follow-up from the ADAURA trial, which looked at osimertinib as adjuvant therapy in patients with resected EGFR-mutated disease. The results raise the question of whether the drug needs to be given indefinitely.

Next, he discusses an analysis of data from the ADAURA trial that looked at longitudinal monitoring of circulating tumor DNA (ctDNA) levels. This revealed that both baseline ctDNA and ctDNA clearance were predictive of later recurrence.

Dr West moves on to a large global study that demonstrated a clear link between air pollution and lung cancer. Pollution was shown to be a tumor promoter of rare driver mutations in normal lung tissue.

After discussing disappointing data from CANOPY-A indicating that adjuvant canakinumab does not improve survival outcomes, he closes with an examination of the PATHFINDER study. This involved more than 6600 patients who were screened for cancer after a single blood test. Although the study identified cancer in 1.4% of participants, the low positive predictive value raises questions over the wider application of this test.

--

Associate Professor, Department of Medical Oncology, City of Hope Comprehensive Cancer Care, Duarte, California; Medical Director, AccessHope, Los Angeles, California

Howard (Jack) West, MD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; Eli Lilly; EQRx; Genentech/Roche; Merck; Mirati; Pfizer; Regeneron; Takeda

Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Merck

Professor Pardeep Jhund, from the University of Glasgow, United Kingdom, discusses highlights in diabetes and heart disease presented at the European Society of Cardiology Congress 2022.

He begins with a Danish study of the causes of excess mortality in individuals who have diabetes but do not have coronary artery disease. This showed that, even in these patients, greater efforts are required to improve outcomes.

A second Danish epidemiologic study examines the prevalence of diabetic neuropathy and cardiovascular outcomes. Worryingly, it found that around half of patients did not have their urinary albumin measured.

Next, Prof Jhund examines a follow-up analysis of the DANISH trial, which showed that implantable cardioverter-defibrillators were effective in reducing mortality, but only in individuals without diabetes.

He moves on to a pooled analysis of DECLARE-TIMI 58 and DAPA-CKD, which revealed that dapagliflozin consistently reduced kidney and cardiovascular events regardless of baseline eGFR and urinary albumin.

Finally, he discusses a large study addressing adherence rates for drugs in type 2 diabetes. The data on more than 38,000 patients showed that initiating therapy with an SGLT2 inhibitor or a GLP-1R agonist was associated with comparably high rates of adherence, which were unaffected by the presence or absence of cardiovascular disease.

--

Professor of Cardiology and Epidemiology, University of Glasgow; Honorary Consultant Cardiologist, Queen Elizabeth University Hospital, Glasgow, Scotland

Pardeep Jhund, PhD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Global Clinical Trial Partners

Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Novartis

Received research grant from: AstraZeneca; Boehringer Ingelheim; Analog Devices

Professor Pardeep Jhund, from the University of Glasgow, United Kingdom, discusses highlights in diabetes and heart disease presented at the European Society of Cardiology Congress 2022.

He begins with a Danish study of the causes of excess mortality in individuals who have diabetes but do not have coronary artery disease. This showed that, even in these patients, greater efforts are required to improve outcomes.

A second Danish epidemiologic study examines the prevalence of diabetic neuropathy and cardiovascular outcomes. Worryingly, it found that around half of patients did not have their urinary albumin measured.

Next, Prof Jhund examines a follow-up analysis of the DANISH trial, which showed that implantable cardioverter-defibrillators were effective in reducing mortality, but only in individuals without diabetes.

He moves on to a pooled analysis of DECLARE-TIMI 58 and DAPA-CKD, which revealed that dapagliflozin consistently reduced kidney and cardiovascular events regardless of baseline eGFR and urinary albumin.

Finally, he discusses a large study addressing adherence rates for drugs in type 2 diabetes. The data on more than 38,000 patients showed that initiating therapy with an SGLT2 inhibitor or a GLP-1R agonist was associated with comparably high rates of adherence, which were unaffected by the presence or absence of cardiovascular disease.

--

Professor of Cardiology and Epidemiology, University of Glasgow; Honorary Consultant Cardiologist, Queen Elizabeth University Hospital, Glasgow, Scotland

Pardeep Jhund, PhD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Global Clinical Trial Partners

Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Novartis

Received research grant from: AstraZeneca; Boehringer Ingelheim; Analog Devices

Professor Pardeep Jhund, from the University of Glasgow, United Kingdom, discusses highlights in diabetes and heart disease presented at the European Society of Cardiology Congress 2022.

He begins with a Danish study of the causes of excess mortality in individuals who have diabetes but do not have coronary artery disease. This showed that, even in these patients, greater efforts are required to improve outcomes.

A second Danish epidemiologic study examines the prevalence of diabetic neuropathy and cardiovascular outcomes. Worryingly, it found that around half of patients did not have their urinary albumin measured.

Next, Prof Jhund examines a follow-up analysis of the DANISH trial, which showed that implantable cardioverter-defibrillators were effective in reducing mortality, but only in individuals without diabetes.

He moves on to a pooled analysis of DECLARE-TIMI 58 and DAPA-CKD, which revealed that dapagliflozin consistently reduced kidney and cardiovascular events regardless of baseline eGFR and urinary albumin.

Finally, he discusses a large study addressing adherence rates for drugs in type 2 diabetes. The data on more than 38,000 patients showed that initiating therapy with an SGLT2 inhibitor or a GLP-1R agonist was associated with comparably high rates of adherence, which were unaffected by the presence or absence of cardiovascular disease.

--

Professor of Cardiology and Epidemiology, University of Glasgow; Honorary Consultant Cardiologist, Queen Elizabeth University Hospital, Glasgow, Scotland

Pardeep Jhund, PhD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Global Clinical Trial Partners

Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Novartis

Received research grant from: AstraZeneca; Boehringer Ingelheim; Analog Devices